156 related articles for article (PubMed ID: 35326637)
1. Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in
Passeri T; Dahmani A; Masliah-Planchon J; Naguez A; Michou M; El Botty R; Vacher S; Bouarich R; Nicolas A; Polivka M; Franck C; Schnitzler A; Némati F; Roman-Roman S; Bourdeaut F; Adle-Biassette H; Mammar H; Froelich S; Bièche I; Decaudin D
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326637
[TBL] [Abstract][Full Text] [Related]
2. The mutational landscape of skull base and spinal chordomas and the identification of potential prognostic and theranostic biomarkers.
Passeri T; Gutman T; Hamza A; Adle-Biassette H; Girard E; Beaurepere R; Tariq Z; Mariani O; Dahmani A; Bourneix C; Abbritti R; Driouch K; Bohec M; Servant N; Baulande S; Decaudin D; Guichard JP; Calugaru V; Feuvret L; Guinebretière JM; Champion L; Bièche I; Froelich S; Mammar H; Masliah-Planchon J
J Neurosurg; 2023 Nov; 139(5):1270-1280. PubMed ID: 37029667
[TBL] [Abstract][Full Text] [Related]
3.
Passeri T; Dahmani A; Masliah-Planchon J; El Botty R; Courtois L; Vacher S; Marangoni E; Nemati F; Roman-Roman S; Adle-Biassette H; Mammar H; Froelich S; Bièche I; Decaudin D
Front Oncol; 2022; 12():960720. PubMed ID: 36505864
[TBL] [Abstract][Full Text] [Related]
4. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival.
Bai J; Shi J; Li C; Wang S; Zhang T; Hua X; Zhu B; Koka H; Wu HH; Song L; Wang D; Wang M; Zhou W; Ballew BJ; Zhu B; Hicks B; Mirabello L; Parry DM; Zhai Y; Li M; Du J; Wang J; Zhang S; Liu Q; Zhao P; Gui S; Goldstein AM; Zhang Y; Yang XR
Nat Commun; 2021 Feb; 12(1):757. PubMed ID: 33536423
[TBL] [Abstract][Full Text] [Related]
5. Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy.
Gounder MM; Zhu G; Roshal L; Lis E; Daigle SR; Blakemore SJ; Michaud NR; Hameed M; Hollmann TJ
Clin Cancer Res; 2019 Apr; 25(7):2064-2071. PubMed ID: 30642912
[TBL] [Abstract][Full Text] [Related]
6. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
Wang L; Zehir A; Nafa K; Zhou N; Berger MF; Casanova J; Sadowska J; Lu C; Allis CD; Gounder M; Chandhanayingyong C; Ladanyi M; Boland PJ; Hameed M
Genes Chromosomes Cancer; 2016 Jul; 55(7):591-600. PubMed ID: 27072194
[TBL] [Abstract][Full Text] [Related]
7. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
[TBL] [Abstract][Full Text] [Related]
8. Establishment and preclinical application of a patient-derived xenograft model for uterine cancer.
Jeong SY; Cho YJ; Ryu JY; Choi JJ; Hwang JR; Kim B; Lee YY; Kim HS; Lee JW
Gynecol Oncol; 2021 Jul; 162(1):173-181. PubMed ID: 33972086
[TBL] [Abstract][Full Text] [Related]
9. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
[TBL] [Abstract][Full Text] [Related]
10. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
11. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
12. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of a primary human chordoma xenograft model.
Siu IM; Salmasi V; Orr BA; Zhao Q; Binder ZA; Tran C; Ishii M; Riggins GJ; Hann CL; Gallia GL
J Neurosurg; 2012 Apr; 116(4):801-9. PubMed ID: 22283186
[TBL] [Abstract][Full Text] [Related]
14. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
[No Abstract] [Full Text] [Related]
15. Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy.
Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; De Stanchina E; Dela Cruz FS; Kung AL; Gounder M; Kentsis A
bioRxiv; 2023 Dec; ():. PubMed ID: 36798379
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.
Raychaudhuri R; Ujjani C
Onco Targets Ther; 2022; 15():193-199. PubMed ID: 35250278
[TBL] [Abstract][Full Text] [Related]
17. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
18. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
20. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
